vs
Side-by-side financial comparison of LESAKA TECHNOLOGIES INC (LSAK) and NEOGENOMICS INC (NEO). Click either name above to swap in a different company.
LESAKA TECHNOLOGIES INC is the larger business by last-quarter revenue ($3.0B vs $186.7M, roughly 16.0× NEOGENOMICS INC). LESAKA TECHNOLOGIES INC runs the higher net margin — 0.0% vs -57.9%, a 57.9% gap on every dollar of revenue. On growth, NEOGENOMICS INC posted the faster year-over-year revenue change (11.1% vs 0.2%). Over the past eight quarters, LESAKA TECHNOLOGIES INC's revenue compounded faster (352.8% CAGR vs 6.5%).
Lesaka Technologies is a South-African financial technology company that is listed on the NASDAQ and Johannesburg Stock Exchange. Lesaka’s primary focus is on financial inclusion, offering financial services to previously underserved communities and merchants.
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.
LSAK vs NEO — Head-to-Head
Income Statement — Q1 FY2027 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.0B | $186.7M |
| Net Profit | $437.0K | $-108.0M |
| Gross Margin | — | 43.3% |
| Operating Margin | 2.2% | 46.9% |
| Net Margin | 0.0% | -57.9% |
| Revenue YoY | 0.2% | 11.1% |
| Net Profit YoY | — | 42.0% |
| EPS (diluted) | — | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 26 | $3.0B | — | ||
| Q1 26 | — | $186.7M | ||
| Q4 25 | $178.7M | $190.2M | ||
| Q3 25 | $171.4M | $187.8M | ||
| Q2 25 | $168.5M | $181.3M | ||
| Q1 25 | $161.4M | $168.0M | ||
| Q4 24 | $176.2M | $172.0M | ||
| Q3 24 | $153.6M | $167.8M |
| Q3 26 | $437.0K | — | ||
| Q1 26 | — | $-108.0M | ||
| Q4 25 | $3.6M | — | ||
| Q3 25 | $-4.3M | $-27.1M | ||
| Q2 25 | $-28.4M | $-45.1M | ||
| Q1 25 | $-22.1M | $-25.9M | ||
| Q4 24 | $-32.5M | — | ||
| Q3 24 | $-4.5M | $-17.7M |
| Q3 26 | — | — | ||
| Q1 26 | — | 43.3% | ||
| Q4 25 | 31.4% | 43.8% | ||
| Q3 25 | 30.9% | 42.8% | ||
| Q2 25 | 28.9% | 42.6% | ||
| Q1 25 | 27.5% | 43.6% | ||
| Q4 24 | 25.7% | 44.9% | ||
| Q3 24 | 22.6% | 44.6% |
| Q3 26 | 2.2% | — | ||
| Q1 26 | — | 46.9% | ||
| Q4 25 | 1.2% | -7.1% | ||
| Q3 25 | 0.2% | -14.4% | ||
| Q2 25 | -16.7% | -26.3% | ||
| Q1 25 | 0.4% | -16.6% | ||
| Q4 24 | 0.3% | -10.7% | ||
| Q3 24 | -0.0% | -12.6% |
| Q3 26 | 0.0% | — | ||
| Q1 26 | — | -57.9% | ||
| Q4 25 | 2.0% | — | ||
| Q3 25 | -2.5% | -14.4% | ||
| Q2 25 | -16.9% | -24.9% | ||
| Q1 25 | -13.7% | -15.4% | ||
| Q4 24 | -18.4% | — | ||
| Q3 24 | -3.0% | -10.5% |
| Q3 26 | — | — | ||
| Q1 26 | — | $-0.13 | ||
| Q4 25 | $0.04 | — | ||
| Q3 25 | $-0.05 | — | ||
| Q2 25 | $-0.40 | — | ||
| Q1 25 | $-0.27 | — | ||
| Q4 24 | $-0.40 | — | ||
| Q3 24 | $-0.07 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.5B | $146.1M |
| Total DebtLower is stronger | $3.2B | — |
| Stockholders' EquityBook value | — | $828.8M |
| Total Assets | $11.5B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 26 | $1.5B | — | ||
| Q1 26 | — | $146.1M | ||
| Q4 25 | $69.5M | $159.6M | ||
| Q3 25 | $72.2M | $164.1M | ||
| Q2 25 | $76.5M | $154.7M | ||
| Q1 25 | $71.0M | $346.2M | ||
| Q4 24 | $60.6M | $367.0M | ||
| Q3 24 | $49.7M | $362.0M |
| Q3 26 | $3.2B | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $216.8M | $341.9M | ||
| Q3 25 | $208.1M | — | ||
| Q2 25 | $200.8M | — | ||
| Q1 25 | $194.7M | — | ||
| Q4 24 | $148.7M | $541.1M | ||
| Q3 24 | $148.5M | — |
| Q3 26 | — | — | ||
| Q1 26 | — | $828.8M | ||
| Q4 25 | $180.6M | $836.6M | ||
| Q3 25 | $170.4M | $838.3M | ||
| Q2 25 | $161.6M | $854.0M | ||
| Q1 25 | $185.2M | $888.3M | ||
| Q4 24 | $193.3M | $902.3M | ||
| Q3 24 | $184.2M | $908.2M |
| Q3 26 | $11.5B | — | ||
| Q1 26 | — | $1.3B | ||
| Q4 25 | $704.6M | $1.4B | ||
| Q3 25 | $652.9M | $1.4B | ||
| Q2 25 | $653.7M | $1.4B | ||
| Q1 25 | $649.2M | $1.6B | ||
| Q4 24 | $640.6M | $1.6B | ||
| Q3 24 | $551.9M | $1.6B |
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.20× | 0.41× | ||
| Q3 25 | 1.22× | — | ||
| Q2 25 | 1.24× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 0.77× | 0.60× | ||
| Q3 24 | 0.81× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-8.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 26 | — | — | ||
| Q1 26 | — | $-8.1M | ||
| Q4 25 | $-10.9M | $1.3M | ||
| Q3 25 | $8.9M | $8.9M | ||
| Q2 25 | $-9.1M | $20.3M | ||
| Q1 25 | $10.7M | $-25.3M | ||
| Q4 24 | $-9.2M | $9.8M | ||
| Q3 24 | $-4.1M | $9.2M |
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $-14.8M | $-6.5M | ||
| Q3 25 | $4.9M | $570.0K | ||
| Q2 25 | $-13.2M | $14.0M | ||
| Q1 25 | $7.8M | $-29.8M | ||
| Q4 24 | $-15.5M | $-1.8M | ||
| Q3 24 | $-8.1M | $-1.6M |
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | -8.3% | -3.4% | ||
| Q3 25 | 2.9% | 0.3% | ||
| Q2 25 | -7.8% | 7.7% | ||
| Q1 25 | 4.9% | -17.8% | ||
| Q4 24 | -8.8% | -1.0% | ||
| Q3 24 | -5.3% | -0.9% |
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 2.2% | 4.1% | ||
| Q3 25 | 2.3% | 4.4% | ||
| Q2 25 | 2.4% | 3.5% | ||
| Q1 25 | 1.7% | 2.7% | ||
| Q4 24 | 3.6% | 6.7% | ||
| Q3 24 | 2.6% | 6.4% |
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | -2.99× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
